Enovis Corp revenue by segment ENOV

Enovis Corp splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Prevention And Recovery at $1.1 billion, 51% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line
FY 2026
Oct 2, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
FY 2015
Dec 31, 2015
Revenue
2,306
2,248
2,108
1,707
1,563
1,426
1,121
3,327
3,300
3,186
3,434
Fabrication Technology
—
—
—
—
—
2,428
+24.5%
share 170.3%
1,950
-13.2%
share 174.0%
2,247
share 67.5%
1,937
share 58.7%
—
—
Prevention And Recovery
1,129
-1.1%
share 48.9%
1,137
+3.6%
share 50.6%
1,098
+2.0%
share 52.1%
1,077
+4.8%
share 63.1%
1,028
+0.2%
share 65.7%
1,026
share 71.9%
—
—
—
—
—
Medical Technology
—
—
—
—
—
—
1,121
+3.7%
share 100.0%
1,080
share 32.5%
—
—
—
Reconstructive
1,178
+7.8%
share 51.1%
1,111
+10.0%
share 49.4%
1,010
+60.2%
share 47.9%
630
+17.7%
share 36.9%
535
+33.8%
share 34.3%
400
share 28.1%
—
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Listed as
ENOV (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Lewisville, TX
SEC filer status
Large accelerated filer
SEC CIK
1420800
Former names
Colfax CORP (until Mar 18, 2022)

Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.